Amgen Inc. Income (Loss) from Equity Method Investments
Amgen Inc. (AMGN) reported Income (Loss) from Equity Method Investments of $10.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-14.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2025-02-14
- Amgen Inc. income (loss) from equity method investments for the quarter ending 2024-12-31 was -$1.00M.
- Amgen Inc. income (loss) from equity method investments for the quarter ending 2024-09-30 was -$28.00M, a 300.00% decline year-over-year.
- Amgen Inc. income (loss) from equity method investments for the quarter ending 2024-06-30 was $12.00M.
- Amgen Inc. income (loss) from equity method investments for the quarter ending 2024-03-31 was $27.00M, a 12.90% decline year-over-year.
- Amgen Inc. income (loss) from equity method investments for fiscal 2024 was $10.00M.
- Amgen Inc. income (loss) from equity method investments for fiscal 2023 was -$11.00M.
- Amgen Inc. income (loss) from equity method investments for fiscal 2022 was -$891.00M.
- Amgen Inc. income (loss) from equity method investments for fiscal 2021 was -$33.00M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | -$29.00M derived: sum of 2 quarters · filed 2025-02-14 | -$17.00M derived: sum of 3 quarters · filed 2025-02-14 | $10.00M 10-K · filed 2025-02-14 |
| 2024-09-30 | -$28.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$16.00M derived: sum of 2 quarters · filed 2024-10-31 | $11.00M 10-Q · filed 2024-10-31 | -$17.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2024-06-30 | $12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $39.00M 10-Q · filed 2024-08-07 | $11.00M derived: sum of 3 quarters · filed 2025-02-14 | $25.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2024-03-31 | $27.00M 10-Q · filed 2024-05-03 | -$1.00M derived: sum of 2 quarters · filed 2025-02-14 | $13.00M derived: sum of 3 quarters · filed 2025-02-14 | -$15.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-12-31 | -$28.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | -$14.00M derived: sum of 2 quarters · filed 2025-02-14 | -$42.00M derived: sum of 3 quarters · filed 2025-02-14 | -$11.00M 10-K · filed 2025-02-14 |
| 2023-09-30 | $14.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$14.00M derived: sum of 2 quarters · filed 2024-10-31 | $17.00M 10-Q · filed 2024-10-31 | -$161.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | -$28.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $3.00M 10-Q · filed 2024-08-07 | -$175.00M derived: sum of 3 quarters · filed 2025-02-14 | -$391.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $31.00M 10-Q · filed 2024-05-03 | -$147.00M derived: sum of 2 quarters · filed 2025-02-14 | -$363.00M derived: sum of 3 quarters · filed 2025-02-14 | -$555.00M derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | -$178.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | -$394.00M derived: sum of 2 quarters · filed 2025-02-14 | -$586.00M derived: sum of 3 quarters · filed 2025-02-14 | -$891.00M 10-K · filed 2025-02-14 |
| 2022-09-30 | -$216.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | -$408.00M derived: sum of 2 quarters · filed 2023-10-31 | -$713.00M 10-Q · filed 2023-10-31 | -$616.00M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-30 | -$192.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$497.00M 10-Q · filed 2023-08-04 | -$400.00M derived: sum of 3 quarters · filed 2024-02-14 | -$566.00M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-31 | -$305.00M 10-Q · filed 2023-04-28 | -$208.00M derived: sum of 2 quarters · filed 2024-02-14 | -$374.00M derived: sum of 3 quarters · filed 2024-02-14 | -$423.00M derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-31 | $97.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | -$69.00M derived: sum of 2 quarters · filed 2024-02-14 | -$118.00M derived: sum of 3 quarters · filed 2024-02-14 | -$33.00M 10-K · filed 2024-02-14 |
| 2021-09-30 | -$166.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$215.00M derived: sum of 2 quarters · filed 2022-11-04 | -$130.00M 10-Q · filed 2022-11-04 | |
| 2021-06-30 | -$49.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $36.00M 10-Q · filed 2022-08-05 | ||
| 2021-03-31 | $85.00M 10-Q · filed 2022-04-28 | |||
| 2020-12-31 | -$65.00M 10-K · filed 2023-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GILEAD SCIENCES, INC. (GILD) | United States | $185.522B | -48.37 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |